Cargando…
Structural Basis for the Inhibition of Cyclin G‐Associated Kinase by Gefitinib
Gefitinib is the molecular target drug for advanced non‐small‐cell lung cancer. The primary target of gefitinib is the positive mutation of epidermal growth factor receptor, but it also inhibits cyclin G‐associated kinase (GAK). To reveal the molecular bases of GAK and gefitinib binding, structure a...
Autores principales: | Ohbayashi, Naomi, Murayama, Kazutaka, Kato‐Murayama, Miyuki, Kukimoto‐Niino, Mutsuko, Uejima, Tamami, Matsuda, Takayoshi, Ohsawa, Noboru, Yokoyoma, Shigeyuki, Nojima, Hiroshi, Shirouzu, Mikako |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6129943/ https://www.ncbi.nlm.nih.gov/pubmed/30214852 http://dx.doi.org/10.1002/open.201800177 |
Ejemplares similares
-
Cell-free synthesis of functional antibody fragments to provide a structural basis for antibody–antigen interaction
por: Matsuda, Takayoshi, et al.
Publicado: (2018) -
Structural Insight into TNIK Inhibition
por: Kukimoto-Niino, Mutsuko, et al.
Publicado: (2022) -
TNIK inhibition abrogates colorectal cancer stemness
por: Masuda, Mari, et al.
Publicado: (2016) -
Cell-permeable Carboxyl-terminal p27(Kip1) Peptide Exhibits Anti-tumor Activity by Inhibiting Pim-1 Kinase
por: Morishita, Daisuke, et al.
Publicado: (2011) -
A conserved PI(4,5)P2–binding domain is critical for immune regulatory function of DOCK8
por: Sakurai, Tetsuya, et al.
Publicado: (2021)